📣 VC round data is live. Check it out!
- Public Comps
- Intermediate Capital Group
Intermediate Capital Group Valuation Multiples
Discover Intermediate Capital Group's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Covivio, Brookfield Renewable, Guolian Securities, VZ VermögensZentrum and more.
Intermediate Capital Group Overview
About Intermediate Capital Group
ICG Plc is an asset management firm that divides its business model into two segments: a fund management company and an investment company. The fund management company is the operating business of the group that sources and manages investments in the European, Asia-Pacific, and North American markets. It allocates capital to corporate investments, capital market investments, real assets, and private equity secondary market transactions. The investment company co-invests alongside third parties in new or existing funds. Its plan emphasizes a growth-oriented, activist, and long-term approach to investing. It generates revenue through interest income and, secondarily, through management fees.
Founded
1988
HQ

Employees
686
Website
Sectors
Financials (LTM)
EV
$16B
Valuation Multiples
Start free trialIntermediate Capital Group Financials
Intermediate Capital Group reported last 12-month revenue of $1B and EBITDA of $811M.
In the same LTM period, Intermediate Capital Group generated $811M in EBITDA and $651M in net income.
Revenue (LTM)
Intermediate Capital Group P&L
In the most recent fiscal year, Intermediate Capital Group reported revenue of $1B and net income of $607M.
Intermediate Capital Group is profitable as of last fiscal year, with net margin of 47%.
Financial data powered by Morningstar, Inc.
Intermediate Capital Group Stock Performance
Intermediate Capital Group has current market cap of $7B, and enterprise value of $16B.
Market Cap Evolution
Intermediate Capital Group's stock price is $24.70.
Intermediate Capital Group share price decreased by 1.7% in the last 30 days, and by 4.1% in the last year.
Intermediate Capital Group has an EPS (earnings per share) of $2.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16B | $7B | 0.1% | -1.7% | 19.7% | -4.1% | $2.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIntermediate Capital Group Valuation Multiples
Intermediate Capital Group trades at 11.2x EV/Revenue multiple, and 19.4x EV/EBITDA.
EV / Revenue (LTM)
Intermediate Capital Group Financial Valuation Multiples
As of June 3, 2026, Intermediate Capital Group has market cap of $7B and EV of $16B.
Intermediate Capital Group has a P/E ratio of 11.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Intermediate Capital Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Intermediate Capital Group Margins & Growth Rates
Intermediate Capital Group grew revenue by 8% and net profit by 6% in the last fiscal year.
In the most recent fiscal year, Intermediate Capital Group reported net margin of 47%.
Intermediate Capital Group Margins
Intermediate Capital Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Intermediate Capital Group Operational KPIs
Intermediate Capital Group's revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.8M for the same period.
Intermediate Capital Group's Rule of 40 is 63% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Intermediate Capital Group's Rule of X is 71% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Intermediate Capital Group Competitors
Intermediate Capital Group competitors include Covivio, Brookfield Renewable, Guolian Securities, VZ VermögensZentrum, China CITIC Financial, Compagnie du Cambodge, China Industrial Securities, KBC Ancora, Migdal Group and Voya Financial.
Most Intermediate Capital Group public comparables operate across Asset Management.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 11.3x | 22.4x | 11.6x | 24.7x | |||
| 3.9x | 3.8x | 5.2x | 5.0x | |||
| 0.7x | 0.8x | 1.5x | - | |||
| 7.5x | 7.3x | 14.4x | 14.0x | |||
| 16.6x | 17.5x | 38.1x | 35.9x | |||
| 36.4x | - | 103.5x | - | |||
| 11.1x | 10.5x | - | - | |||
| 18.4x | 18.4x | - | - | |||
This data is available for Pro users. Sign up to see all Intermediate Capital Group competitors and their valuation data. Start Free Trial | ||||||
Intermediate Capital Group VC Funding History
Before going public, Intermediate Capital Group raised $728M in total equity funding, across 1 round.
Last private valuation of Intermediate Capital Group was $7B, after raising $728M in November 2025 from Amundi.
Intermediate Capital Group Funding Rounds
Acquisitions by Intermediate Capital Group
Intermediate Capital Group has acquired 25 companies to date.
Last acquisition by Intermediate Capital Group was on June 11th 2024. Intermediate Capital Group acquired DGS for undisclosed valuation.
Latest Acquisitions by Intermediate Capital Group
| Description | DGS is an Italian ICT group established in 1997 delivering system integration and managed services for large enterprises. It covers planning, development, and maintenance of infrastructures using Cisco, Microsoft, and Oracle technologies. With bimodal IT delivery, DGS serves public sector and finance clients across Italy. | Law Business Research is a London-based publisher of guides on international business law across 50 practice areas. Titles include Getting the Deal Through series covering mergers, antitrust, and arbitration in 100 jurisdictions. The company serves law firms and corporations with annual updates and online databases. Acquired by Reliance in 2021, it hosts webinars featuring contributors from firms like Baker McKenzie. | Seaway Plastics Engineering is a Wisconsin-based plastic injection molding company specializing in prototype injection molding, low-volume production, and mold making services. | Canopy Healthcare is a New Zealand-based network of medical facilities that operates diagnostic clinics, an oncology clinic, and private breast surgical and diagnostic centers. Headquartered in Auckland, the group delivers specialized services including mammography, ultrasound imaging, and cancer treatment programs across multiple locations in the North Island. Established to address growing demand for accessible diagnostics, Canopy Healthcare integrates radiology and surgical expertise to support early detection and patient care in regions like Waikato and Bay of Plenty. | |
| HQ Country | |||||
| HQ City | Rome | London | Tampa, FL | Auckland | |
| Deal Date | 11 Jun 2024 | 20 May 2024 | 23 Jun 2022 | 12 May 2022 | |
| Valuation | undisclosed | $814M | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Intermediate Capital Group acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Intermediate Capital Group
Intermediate Capital Group has invested in 15 companies to date.
Latest investment by Intermediate Capital Group was on January 7th 2026. Intermediate Capital Group invested in Mediar Therapeutics in their $76M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by Intermediate Capital Group
| Description | Mediar Therapeutics is a Cambridge, Massachusetts-headquartered biotechnology firm focused on pre-clinical therapeutics targeting fibrosis in organs such as lungs, liver, and kidneys. Its pipeline includes small-molecule inhibitors of key fibrotic mediators like TNIK and MRCK, aiming to halt disease progression in idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis. Founded in 2019, the company collaborates with academic institutions and leverages proprietary screening platforms to advance candidates toward clinical trials. Mediar Therapeutics operates from facilities in the Kendall Square biotech hub, positioning it among emerging players in fibrotic disease innovation. | Wugen is a St. Louis-headquartered biotechnology company engineering off-the-shelf natural killer cell therapies from healthy donors for solid tumors, acute myeloid leukemia, and T-cell malignancies. Its pipeline features enhanced NK cells and CAR-T products advancing through clinical trials in the United States. | Draig Therapeutics is a Cork-based clinical-stage biopharmaceutical firm developing therapies for schizophrenia and other neuropsychiatric disorders. Its lead candidate targets glutamate signaling pathways in Phase I trials for treatment-resistant conditions. | Konecta is a Colombian company specializing in industrial automation and custom machinery design for manufacturing sectors. It engineers robotic assembly lines, conveyor systems, and control panels for food processing, pharmaceuticals, and packaging industries across Latin America, providing turnkey solutions that include PLC programming, vision systems, and safety integrations. | |
| HQ Country | |||||
| HQ City | - | St Louis, MO | Cardiff | CĂłrdoba | |
| Deal Date | 7 Jan 2026 | 27 Aug 2025 | 18 Jun 2025 | 12 Feb 2025 | |
| Round | Series B | Series C | Series A | Undisclosed stage | |
| Raised | $76M | $115M | $140M | $78M | |
| Investors | Alexandria Real Estate; Amplitude Venture Capital; Asahi Kasei Pharma; Intermediate Capital Group; Longwood Fund | Abingworth; Aisling Capital; Fidelity; Intermediate Capital Group; Lightchain Capital; LYZZ Capital; RiverVest; Tybourne Capital Management | Access Biotechnology; Canaan Partners; Intermediate Capital Group; Sanofi Ventures; Schroders Capital; SR One; SV Health Investors | Intermediate Capital Group | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Intermediate Capital Group investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Intermediate Capital Group
| When was Intermediate Capital Group founded? | Intermediate Capital Group was founded in 1988. |
| Where is Intermediate Capital Group headquartered? | Intermediate Capital Group is headquartered in United Kingdom. |
| How many employees does Intermediate Capital Group have? | As of today, Intermediate Capital Group has over 686 employees. |
| Who is the CEO of Intermediate Capital Group? | Intermediate Capital Group's CEO is Benoit Durteste. |
| Is Intermediate Capital Group publicly listed? | Yes, Intermediate Capital Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Intermediate Capital Group? | Intermediate Capital Group trades under ICG ticker. |
| When did Intermediate Capital Group go public? | Intermediate Capital Group went public in 1994. |
| Who are competitors of Intermediate Capital Group? | Intermediate Capital Group main competitors include Covivio, Brookfield Renewable, Guolian Securities, VZ VermögensZentrum, China CITIC Financial, Compagnie du Cambodge, China Industrial Securities, KBC Ancora, Migdal Group, Voya Financial. |
| What is the current market cap of Intermediate Capital Group? | Intermediate Capital Group's current market cap is $7B. |
| What is the current revenue of Intermediate Capital Group? | Intermediate Capital Group's last 12 months revenue is $1B. |
| What is the current revenue growth of Intermediate Capital Group? | Intermediate Capital Group revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Intermediate Capital Group? | Current revenue multiple of Intermediate Capital Group is 11.2x. |
| What is the current EBITDA of Intermediate Capital Group? | Intermediate Capital Group's last 12 months EBITDA is $811M. |
| What is Intermediate Capital Group's EBITDA margin? | Intermediate Capital Group's last 12 months EBITDA margin is 58%. |
| What is the current EV/EBITDA multiple of Intermediate Capital Group? | Current EBITDA multiple of Intermediate Capital Group is 19.4x. |
| What is the current FCF of Intermediate Capital Group? | Intermediate Capital Group's last 12 months FCF is $823M. |
| What is Intermediate Capital Group's FCF margin? | Intermediate Capital Group's last 12 months FCF margin is 59%. |
| What is the current EV/FCF multiple of Intermediate Capital Group? | Current FCF multiple of Intermediate Capital Group is 19.1x. |
| How many companies Intermediate Capital Group has acquired to date? | As of June 2026, Intermediate Capital Group has acquired 25 companies. |
| What was the largest acquisition by Intermediate Capital Group? | $4B acquisition of Groupe Circet on 25th May 2021 was the largest M&A Intermediate Capital Group has done to date. |
| What companies Intermediate Capital Group acquired? | Intermediate Capital Group acquired Groupe Circet, Doc Generici, Law Business Research, Infra Group, Park Holidays UK, proALPHA, Broadstone, Grupo Garnica Plywood, Everlight Radiology, Esperi Care, and 15 other companies. |
| In how many companies Intermediate Capital Group has invested to date? | As of June 2026, Intermediate Capital Group has invested in 15 companies. |
| What was the last Intermediate Capital Group investment? | On 7th January 2026 Intermediate Capital Group invested in Mediar Therapeutics, participating in a $76M Series B round, alongside Alexandria Real Estate, Amplitude Venture Capital, Asahi Kasei Pharma, and Longwood Fund. |
| In what companies Intermediate Capital Group invested in? | Intermediate Capital Group invested in Enfinity Global, YUDO (China) Holdings, Wugen, Amolyt Pharma, Draig Therapeutics, Vitaldent, AMPIN Energy Transition, Workhuman, Astek Group, F2G, Eliem Therapeutics, Konecta, Mediar Therapeutics, Greywolf Therapeutics, and IRIS Software Group. |
See public comps similar to Intermediate Capital Group
Lists including Intermediate Capital Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




